| This week's sponsor is Premier Research. | | | Studying an Addiction Drug? Some Practical Tips To Help
Developing drugs to treat addiction is a complex challenge, and sponsors benefit when they know how addiction trials work. Read our white paper for a closer look. Premier Research. It's what we do. Best. |
Today's Rundown Novartis, already up on CRISPR, CAR-T, looks to new gene editing R&D Arcus Biosciences gains meaty $107M with help from Google Zymeworks pens $50M upfront, $1B-plus biobucks Janssen bispecific pact [Sponsored] Looking Toward Abuse Deterrent Opioids Moving beyond Cas9, Excision licenses CRISPR gene editors CRISPR, Bayer JV tap CureVac for Cas9 mRNA constructs Bill Gates pledges $50M for Alzheimer’s disease fund Concept buy Aquila inks immuno-oncology deal with Macrophage Pharma GI Dynamics loses CE mark over quality nonconformance Featured Story | | | Monday, November 13, 2017 Novartis has penned a new deal with Homology Medicines as it looks to boost its already impressive R&D work in cell and gene therapy. |
|
|
| This week's sponsor is Deloitte. | | | |
Top Stories Monday, November 13, 2017 Immuno-oncology startup Arcus Bioscience has got off another impressive round of funding, just over a year after emerging from stealth with $120 million. Monday, November 13, 2017 Zymeworks must be spending a fortune on pens as it inks yet another deal, this time with Johnson & Johnson’s biotech unit. Monday, November 13, 2017 The complex and intertwined dual epidemics of poorly treated pain and opioid addiction require a combined, artful approach to secure the best possible results for patients. Monday, November 13, 2017 Excision BioTherapeutics has licensed recently discovered CRISPR gene editors from UC Berkeley. The deal gives Excision the exclusive right to use the Cas9 alternatives to treat infectious diseases. Monday, November 13, 2017 CRISPR Therapeutics and its joint venture with Bayer have struck a deal with CureVac. The pact tasks CureVac with developing Cas9 mRNA constructs for use by CRISPR and joint venture Casebia Therapeutics in three in vivo gene-editing liver disease programs. Monday, November 13, 2017 Billionaire Bill Gates has turned his philanthropic eye toward Alzheimer’s disease, with a $50 million investment in the U.K.-based Dementia Discovery Fund. Monday, November 13, 2017 Concept Life Sciences’ recent acquisition of Aquila BioMedical has quickly produced a return—an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs. Monday, November 13, 2017 GI Dynamics has lost the right to sell its Type 2 diabetes and obesity device in the European Union. SGS, the notified body for EndoBarrier, pulled the CE Certificate of Conformity over the weekend in response to nonconformity to medical device quality management system standards. | This week's sponsor is Charles River. | | | |
Resources Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST | Sponsored By Ashfield Healthcare Join this webinar to learn methods that maintain and build sales momentum despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. BioBasics: Biotech for the Non-Scientist November 30-December 1, 2017 | Boston, MA CBI’s Commercial Data Insights 2017 November 28-29, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA Register Today – ISPE Biopharmaceutical Manufacturing Conference December 4th-6th, 2017 | San Francisco, CA BIO Asia International Conference March 19-20, 2018 | Tokyo, Japan Molecular Med Tri-Conference February 11-16, 2018 | San Francisco, CA | 